Page-Banner---MLC-Class-Action.jpg

Proposed shareholder class action against Mesoblast Ltd

The Claim

William Roberts Lawyers is preparing a class action against Mesoblast Limited (ASX: MSB) to recover compensation for persons who acquired an interest in Mesoblast shares traded on the Australian Stock Exchange (ASX) in the period from 22 February 2018 to 17 December 2020 (inclusive) (Relevant Period).

Anyone who acquired an interest in Mesoblast’s ASX shares during the Relevant Period may be entitled to compensation for losses arising out of Mesoblast’s alleged breaches of its continuous disclosure obligations and/or misleading and deceptive conduct.

The proposed class action will allege that during the Relevant Period, Mesoblast engaged in unlawful conduct which misled the market about the company’s developmental stem cell product “remestemcel-L”. 

The Scheme

This class action is required to be conducted as a litigation funding scheme, in accordance with regulations introduced by the Australian government in 2020. A scheme named the “Mesoblast Litigation Funding Scheme” (ARSN 654 319 810) (the Scheme) has been registered with ASIC for this purpose.

As the Scheme’s Responsible Entity, CASL Governance Ltd (CASL) is responsible for issuing the Scheme’s Product Disclosure Statement, as well as any interests in the Scheme.

The litigation will be funded by ICP Funding Pty Ltd and managed by Investor Claim Partner Pty Ltd (ICP), who both are Authorised Representatives of CASL.

Register your interest

If you acquired an interest in Mesoblast shares during the Relevant Period, you can visit https://www.icp.net.au/icp-claims/mesoblast/ where you may register an expression of interest to receive further information about the class action and the Scheme, and apply to participate if you choose to do so.

If you have any questions or issues expressing interest in the class action, please contact: